Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06550609Phase 2Recruiting

Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine

Role: lead

NCT04799236Phase 3Recruiting

Treatment of Mucosal Bolivian Leishmaniasis

Role: lead

NCT03096457Phase 2Completed

Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

Role: lead

NCT03829917Phase 2Completed

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Role: lead

NCT01300975Phase 2Completed

Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

Role: lead

All 5 trials loaded